(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
3 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 5.92%
@ $17.41
发出时间: 15 Feb 2024 @ 03:15
回报率: -9.99%
上一信号: Feb 15 - 02:13
上一信号:
回报率: 1.58 %
Live Chart Being Loaded With Signals
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens...
Stats | |
---|---|
今日成交量 | 604 700 |
平均成交量 | 1.49M |
市值 | 972.00M |
EPS | $0 ( 2024-03-20 ) |
下一个收益日期 | ( $-0.640 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 19.35 |
ATR14 | $0.0180 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-04 | Peters Jeffrey Stuart | Sell | 42 500 | Employee stock option (right to buy) |
2024-04-04 | Peters Jeffrey Stuart | Buy | 42 500 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 42 500 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 147 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 232 | Common Stock |
INSIDER POWER |
---|
43.87 |
Last 100 transactions |
Buy: 2 053 694 | Sell: 721 474 |
音量 相关性
MacroGenics Inc 相关性 - 货币/商品
MacroGenics Inc 财务报表
Annual | 2023 |
营收: | $58.75M |
毛利润: | $58.13M (98.95 %) |
EPS: | $-0.000100 |
FY | 2023 |
营收: | $58.75M |
毛利润: | $58.13M (98.95 %) |
EPS: | $-0.000100 |
FY | 2022 |
营收: | $151.94M |
毛利润: | $144.56M (95.14 %) |
EPS: | $-1.950 |
FY | 2021 |
营收: | $75.64M |
毛利润: | $72.99M (96.50 %) |
EPS: | $-3.30 |
Financial Reports:
No articles found.
MacroGenics Inc
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。